People With High Body Fat PercentageNCT06886048
Effects of Barley Green on Visceral Fat Area in the Human Body and Investigation Into the Associated Mechanism of Intestinal Microbiota
A study testing barley green in people with People With High Body Fat Percentage and People With High Visceral Fat Area, run by Peking University People's Hospital at 1 site in China.
Trial summary
The aim of this study was to investigate the changes in visceral fat area and associated indicators in individuals with high body fat percentage under the intervention of barley green, elucidate the clinical efficacy of barley green on human visceral fat, and preliminarily explore the mechanism by which barley green… Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- People With High Body Fat Percentage, People With High Visceral Fat Area
- What is being tested?
- barley green
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 66 participants
- Where
- 1 siteChina
- Study dates
- 19 Mar 2025to 25 Aug 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18-65 years old, gender is not limited; Body fat percentage exceeding the upper limit of the standard range: male > 20%, female > 28%; Visceral fat area > 100cm2; Willing to accept the assessment and sign informed consent.
Who cannot join
- ① Patients currently receiving weight-loss medications (e.g., incretin-based therapies such as GLP-1 receptor agonists) or medications that improve insulin resistance (e.g., metformin or other insulin-sensitizing agents), or anti-inflammatory agents with documented effects on inflammatory markers (including but not limited to lipid-lowering agents, hypoglycemic agents, antihypertensives, urate-lowering agents, etc.);
- Patients concurrently using nutritional supplements or functional foods (e.g., phytochemicals, health supplements) with demonstrated effects on reducing body fat or visceral adiposity;
- Patients regularly consuming prebiotics, probiotics, or other microbiota-modulating agents;
- Patients with diseases severely affecting nutrient digestion or absorption (e.g., chronic diarrhea, severe constipation, active inflammatory bowel disease, active gastrointestinal ulcers, history of gastrointestinal resection, cholecystitis/post-cholecystectomy syndrome, etc.);
- Patients with cardiovascular/cerebrovascular diseases (e.g., coronary artery disease, heart failure, arrhythmias, cardiomyopathies, cerebral infarction, cerebral hemorrhage, cerebral arteritis), grade 3 hypertension, stroke, chronic hepatitis, malignancies, anemia, psychiatric disorders, cognitive impairment, epilepsy, acute-phase gout, nephrolithiasis, or renal insufficiency;
- ⑥ Patients with hepatic dysfunction (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST] levels exceeding 3 times the upper limit of normal [ULN]) or renal dysfunction (serum creatinine exceeding ULN);
Show all 10Show fewer
- ⑦ Patients with active infectious diseases (e.g., tuberculosis, HIV/AIDS);
- ⑧ Patients with severe allergies to any component of the investigational products;
- ⑨ Pregnant or lactating individuals;
- ⑩ Patients with physical disabilities or other conditions deemed ineligible by investigators (e.g., clinically significant comorbidities not listed above).
Trial locations and contacts
1 site in 1 country.
China1 site
Peking University People's Hospital
Beijing, Xicheng District, 100044
About this study
The aim of this study was to investigate the changes in visceral fat area and associated indicators in individuals with high body fat percentage under the intervention of barley green, elucidate the clinical efficacy of barley green on human visceral fat, and preliminarily explore the mechanism by which barley green influences human visceral fat through gut microbiota analysis. Participants with high body fat percentage were recruited from the Clinical Nutrition Department of Peking University People's Hospital and randomly assigned to either an intervention group or a control group. The intervention group received a regimen combining barley green supplementation with a calorie-restricted balanced diet plan, while the control group followed only the calorie-restricted balanced diet plan. General clinical data were collected, nutritional assessments were conducted, and dynamic analyses of body composition and metabolism were performed. Venous blood samples were obtained for the measurement of metabolic and inflammation-related indices as well as gut microbiota characterization. By observing and comparing differences in visceral fat area and related parameters, as well as gut microbiota profiles between the two groups, this study provides a scientific foundation for the clinical application of barley green in medical nutrition interventions targeting populations with high body fat percentage.
- Being tested
- barley green
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
barley greenDietary supplement
Oral administration: 30 minutes before meals Dosage: 4 g powder, 5 g tablet Frequency: 2 times a day
| Study group | Role | What they receive |
|---|---|---|
| control group | No intervention | Not described |
| intervention group | Experimental | Not described Receives: Dietary Supplement: barley green |
What is being measured
The primary outcome is the main question the study is designed to answer.
visceral fat area in cm2
Visceral fat areas are measured by the Inbody 770 instrument at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks.
Secondary outcomes (71)
height in centimeters
Height in centimeters are measured by Manual Height Ruler at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
weight in kilograms
Weight in kilograms are measured by the Inbody 770 instrument at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
BMI in kg/m^2
Weight and height will be combined to report BMI in kg/m^2 at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
body fat rate in %
Body fat rates are measured by the Inbody 770 instrument at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
muscle mass in kilograms
Muscle masses are measured by the Inbody 770 instrument at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
basal metabolic rate in kcal
Basal metabolic rates are measured by the Inbody 770 instrument at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
skeletal muscle mass in kilograms
Skeletal muscle masses are measured by the Inbody 770 instrument at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
blood pressure in mmHg
Blood pressures are measured by electronic blood pressure monitor at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
waist circumference in millimeters
Waist circumferences are measured by tape measure at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
hip circumference in millimeters
Hip circumferences are measured by tape measure at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
upper arm circumference in millimeters
Upper arm circumferences are measured by tape measure at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
left hand grip strength in pound-force
Left hand grip strengths are measured by grip dynamometer at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
right hand grip strength in pound-force
Right hand grip strengths are measured by grip dynamometer at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
triceps skinfold thickness in millimeters
Triceps skinfold thicknesses are measured by skin fold thickness gauge at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
subscapular horn skinfold thickness in millimeters
Subscapular horn skinfold thicknesses are measured by skin fold thickness gauge at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
abdominal skinfold thickness in millimeters
Abdominal skinfold thicknesses are measured by skin fold thickness gauge at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
food intake dose in grams
Data of food intake doses are taken by food frequency questionnaire and 3-day food diary at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
uric acid levels in umol/L
Uric acid levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
blood glucose in mmol/L
Blood glucose levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
total cholesterol in mmol/L
Total cholesterol levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
triglycerides in mmol/L
Triglycerides levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
high-density lipoprotein cholesterol in mmol/L
High-density lipoprotein cholesterol levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
low-density lipoprotein cholesterol in mmol/L
Low-density lipoprotein cholesterol levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
white blood cell count in 10^9/L
White blood cell counts are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
hemoglobin in g/L
Hemoglobin levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
glutamic-pyruvic transaminase in U/L
Glutamic-pyruvic transaminase levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
glutamic oxalacetic transaminase in U/L
Glutamic oxalacetic transaminase levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
albumin in g/L
Albumin levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
vitamin B6 in ng/mL
Vitamin B6 levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
vitamin B1 in ng/mL
Vitamin B1 levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
vitamin B9 in ng/mL
Vitamin B9 levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
vitamin B5 in ng/mL
Vitamin B5 levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
vitamin B3 in ng/mL
Vitamin B3 levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
vitamin B2 in ng/mL
Vitamin B2 levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
vitamin B12 in ng/mL
Vitamin B12 levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
vitamin A in ng/mL
Vitamin A levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
vitamin D in ng/mL
Vitamin D levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
vitamin E in ng/mL
Vitamin E levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
vitamin K in ng/mL
Vitamin K levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
cobalt in µg/L
Cobalt levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
nickel in µg/L
Nickel levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
selenium in µg/L
Selenium levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
arsenic in µg/L
Arsenic levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
platinum in µg/L
Platinum levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
copper in mg/L
Copper levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
molybdenum in µg/L
Molybdenum levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
zinc in mg/L
Zinc levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
manganese in µg/L
Manganese levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
magnesium in mg/L
Magnesium levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
cadmium in µg/L
Cadmium levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
iron in mg/L
Iron levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
thallium in µg/L
Thallium levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
lead in µg/L
Lead levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
calcium in mg/L
Calcium levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
cortisol in µg/dL
Cortisol levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
growth hormone in ng/mL
Growth hormone levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
fasting insulin in uU/mL
Fasting insulin levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
thyroid-stimulating hormone in uIU/mL
Thyroid-stimulating hormone levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
free thyroxine in pmol/L
Free thyroxine levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
free triiodothyronine in pmol/L
Free triiodothyronine levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
IL-1β in pg/mL
IL-1β levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
IL-6 in pg/mL
IL-6 levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
IL-10 in pg/mL
IL-10 levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
leptin in pg/mL
Leptin levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
adiponectin in µg/mL
Adiponectin levels are measured by blood samples at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
Hardness of liver in kPa
Hardness of liver is measured by Liver Ultrasound Elastography at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
Controlled Attenuation Parameter in dB/m
Controlled Attenuation Parameter is measured by Liver Ultrasound Elastography at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
Alpha diversity (Shannon index, Chao1)
Alpha diversity is measured by fecal specimen assessed by 16S rRNA sequencing at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
Beta diversity (Bray-Curtis dissimilarity)
Beta diversity is measured by fecal specimen assessed by 16S rRNA sequencing at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
Relative abundance of specific taxa (e.g., Firmicutes/Bacteroidetes ratio)
Relative abundance of specific taxa is measured by fecal specimen assessed by 16S rRNA sequencing at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
Predicted functional pathways (via metagenomic analysis)
Predicted functional pathways are analyzed via metagenomic analysis after 16S rRNA sequencing at two time points: the day of enrollment and 8 weeks after enrollment.
Measured: From enrollment to the end of treatment at 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Mar 2025
- Study start19 Mar 2025
- Primary completion3 Jul 2026
- Study completion25 Aug 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for People With High Body Fat PercentageStudies of the same condition, open and under way.
- More trials run by Peking University People's HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 66 participants (actual)
Sponsor and investigators
- Lead sponsor
- Peking University People's Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Cui Mingxuan, Peking University People's Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06886048
- Sponsor's protocol ID
- 2024PHB574-001
- Status last verified
- Sep 2026
- First submitted
- 14 Mar 2025
- Last updated
- 16 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 16 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Barley Green on Visceral Fat Area in the Human Body and Investigation Into the Associated Mechanism of Intestinal Microbiota
- ClinicalTrials.gov ID
- NCT06886048
- Acronym / sponsor ID
- 2024PHB574-001
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 66 participants (actual)
- Lead sponsor
- Peking University People's HospitalUniversity, hospital or other
- Study start
- 19 Mar 2025 (actual)
- Primary completion
- 3 Jul 2026 (actual)
- Study completion
- 25 Aug 2026 (actual)
- First posted
- 20 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study was to investigate the changes in visceral fat area and associated indicators in individuals with high body fat percentage under the intervention of barley green, elucidate the clinical efficacy of barley green on human visceral fat, and preliminarily explore the mechanism by which barley green influences human visceral fat through gut microbiota analysis. Participants with high body fat percentage were recruited from the Clinical Nutrition Department of Peking University People's Hospital and randomly assigned to either an intervention group or a control group. The intervention group received a regimen combining barley green supplementation with a calorie-restricted balanced diet plan, while the control group followed only the calorie-restricted balanced diet plan. General clinical data were collected, nutritional assessments were conducted, and dynamic analyses of body composition and metabolism were performed. Venous blood samples were obtained for the measurement of metabolic and inflammation-related indices as well as gut microbiota characterization. By observing and comparing differences in visceral fat area and related parameters, as well as gut microbiota profiles between the two groups, this study provides a scientific foundation for the clinical application of barley green in medical nutrition interventions targeting populations with high body fat percentage.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| control group | No intervention | – |
| intervention group | Experimental | Dietary Supplement: barley green |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Age 18-65 years old, gender is not limited; Body fat percentage exceeding the upper limit of the standard range: male > 20%, female > 28%; Visceral fat area > 100cm2; Willing to accept the assessment and sign informed consent.
Key exclusion criteria (10 listed)
- ① Patients currently receiving weight-loss medications (e.g., incretin-based therapies such as GLP-1 receptor agonists) or medications that improve insulin resistance (e.g., metformin or other insulin-sensitizing agents), or anti-inflammatory agents with documented effects on inflammatory markers (including but not limited to lipid-lowering agents, hypoglycemic agents, antihypertensives, urate-lowering agents, etc.);
- ⑥ Patients with hepatic dysfunction (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST] levels exceeding 3 times the upper limit of normal [ULN]) or renal dysfunction (serum creatinine exceeding ULN);
- ⑦ Patients with active infectious diseases (e.g., tuberculosis, HIV/AIDS);
- ⑧ Patients with severe allergies to any component of the investigational products;
- ⑨ Pregnant or lactating individuals;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| barley greenOral administration: 30 minutes before meals Dosage: 4 g powder, 5 g tablet Frequency: 2 times a day | Dietary supplement | intervention group |
Primary outcome
visceral fat area in cm2
Time frame: From enrollment to the end of treatment at 8 weeks.
Visceral fat areas are measured by the Inbody 770 instrument at two time points: the day of enrollment and 8 weeks after enrollment.
71 secondary outcomes
height in centimeters
Time frame: From enrollment to the end of treatment at 8 weeks
weight in kilograms
Time frame: From enrollment to the end of treatment at 8 weeks
BMI in kg/m^2
Time frame: From enrollment to the end of treatment at 8 weeks
body fat rate in %
Time frame: From enrollment to the end of treatment at 8 weeks
muscle mass in kilograms
Time frame: From enrollment to the end of treatment at 8 weeks
basal metabolic rate in kcal
Time frame: From enrollment to the end of treatment at 8 weeks
skeletal muscle mass in kilograms
Time frame: From enrollment to the end of treatment at 8 weeks
blood pressure in mmHg
Time frame: From enrollment to the end of treatment at 8 weeks
waist circumference in millimeters
Time frame: From enrollment to the end of treatment at 8 weeks
hip circumference in millimeters
Time frame: From enrollment to the end of treatment at 8 weeks
upper arm circumference in millimeters
Time frame: From enrollment to the end of treatment at 8 weeks
left hand grip strength in pound-force
Time frame: From enrollment to the end of treatment at 8 weeks
right hand grip strength in pound-force
Time frame: From enrollment to the end of treatment at 8 weeks
triceps skinfold thickness in millimeters
Time frame: From enrollment to the end of treatment at 8 weeks
subscapular horn skinfold thickness in millimeters
Time frame: From enrollment to the end of treatment at 8 weeks
abdominal skinfold thickness in millimeters
Time frame: From enrollment to the end of treatment at 8 weeks
food intake dose in grams
Time frame: From enrollment to the end of treatment at 8 weeks
uric acid levels in umol/L
Time frame: From enrollment to the end of treatment at 8 weeks
blood glucose in mmol/L
Time frame: From enrollment to the end of treatment at 8 weeks
total cholesterol in mmol/L
Time frame: From enrollment to the end of treatment at 8 weeks
triglycerides in mmol/L
Time frame: From enrollment to the end of treatment at 8 weeks
high-density lipoprotein cholesterol in mmol/L
Time frame: From enrollment to the end of treatment at 8 weeks
low-density lipoprotein cholesterol in mmol/L
Time frame: From enrollment to the end of treatment at 8 weeks
white blood cell count in 10^9/L
Time frame: From enrollment to the end of treatment at 8 weeks
hemoglobin in g/L
Time frame: From enrollment to the end of treatment at 8 weeks
glutamic-pyruvic transaminase in U/L
Time frame: From enrollment to the end of treatment at 8 weeks
glutamic oxalacetic transaminase in U/L
Time frame: From enrollment to the end of treatment at 8 weeks
albumin in g/L
Time frame: From enrollment to the end of treatment at 8 weeks
vitamin B6 in ng/mL
Time frame: From enrollment to the end of treatment at 8 weeks
vitamin B1 in ng/mL
Time frame: From enrollment to the end of treatment at 8 weeks
vitamin B9 in ng/mL
Time frame: From enrollment to the end of treatment at 8 weeks
vitamin B5 in ng/mL
Time frame: From enrollment to the end of treatment at 8 weeks
vitamin B3 in ng/mL
Time frame: From enrollment to the end of treatment at 8 weeks
vitamin B2 in ng/mL
Time frame: From enrollment to the end of treatment at 8 weeks
vitamin B12 in ng/mL
Time frame: From enrollment to the end of treatment at 8 weeks
vitamin A in ng/mL
Time frame: From enrollment to the end of treatment at 8 weeks
vitamin D in ng/mL
Time frame: From enrollment to the end of treatment at 8 weeks
vitamin E in ng/mL
Time frame: From enrollment to the end of treatment at 8 weeks
vitamin K in ng/mL
Time frame: From enrollment to the end of treatment at 8 weeks
cobalt in µg/L
Time frame: From enrollment to the end of treatment at 8 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Sep 2026.
- Individual participant dataSharing planned: Undecided
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing barley green in people with People With High Body Fat Percentage and People With High Visceral Fat Area, run by Peking University People's Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
visceral fat area in cm2 (time frame: From enrollment to the end of treatment at 8 weeks.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Sep 2026.